Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2024-05-17 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
公司章程（2024年5月）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, share issuance, share transfer, shareholder meetings, and other governance matters. It references relevant laws such as the Company Law of the People's Republic of China and Securities Law, and includes detailed chapters on shareholder meetings, board responsibilities, and capital structure. This document is a governance document that sets out the internal rules and regulations of the company rather than a financial report, announcement, or other filing type. It is not an Annual Report, Interim Report, Earnings Release, nor a regulatory announcement. It is a governance information document describing the company's internal governance framework and rules. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance document, not just an announcement or summary.
2024-05-17 Chinese
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is titled "广州市香雪制药股份有限公司 会计师事务所选聘制度" which translates to "Guangzhou Xiangxue Pharmaceutical Co., Ltd. Auditor Selection System." It details the procedures, requirements, and governance related to the selection, appointment, and replacement of the company's accounting firm (auditor). It references relevant laws and regulations, outlines the responsibilities of the audit committee, board, and shareholders, and includes provisions on audit quality, contract terms, and information disclosure. The document is a formal policy or governance document about auditor selection and oversight, not an audit report, annual report, or announcement of voting results. It does not contain financial statements or audit opinions but rather internal rules and procedures. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (5624 characters) and detailed procedural content support this classification. Confidence is high due to clear alignment with governance policies and absence of financial data or audit results.
2024-05-17 Chinese
关于改选董事、改聘高级管理人员及证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 广州市香雪制药股份有限公司 regarding changes in the company's board of directors, senior management, and securities affairs representatives. It details resignations, appointments, and qualifications of new directors and executives. There is no financial data, earnings information, or report publication mentioned. The content focuses on management and board changes, which fits the category of Board/Management Information (MANG). The document length is 2412 characters, which is consistent with a typical management change announcement rather than a full report or regulatory filing. Therefore, the appropriate classification is MANG.
2024-05-17 Chinese
董事会提名委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board Nomination Committee Working Rules' of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the structure, responsibilities, and procedures of the board nomination committee, including the selection and appointment of directors and senior management. There are no financial statements, earnings data, or regulatory filings related to financial results. The content focuses on governance practices and internal board committee rules. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 2467 characters, which is sufficient for a detailed governance report rather than a brief announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2024-05-17 Chinese
关于修订及制订部分制度的公告
Governance Information Classification · 95% confidence The document is an announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the revision and formulation of several company governance-related systems and rules, including the company charter, independent director work system, board meeting rules, and others. It mentions compliance with relevant laws and regulations and the approval of these changes by the board of directors. The document does not contain financial data or detailed financial reports but focuses on governance and internal rules. It is not a full annual report, interim report, or earnings release. It is not a proxy solicitation or voting results announcement. The content aligns with governance information about company internal rules and board structure. Therefore, the appropriate classification is Governance Information (CGR). The document length is short and it is a direct announcement of governance changes, not a report publication announcement or regulatory filing. Confidence is high due to clear governance focus and detailed listing of governance documents revised or created.
2024-05-17 Chinese
独立董事工作制度
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, responsibilities, nomination, election, and duties of independent directors within the company. It references relevant laws and regulations such as the Company Law, Securities Law, and governance codes. The content is focused on governance practices and internal rules related to board members, specifically independent directors. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document, fitting the category of Governance Information (CGR). The document length is 6881 characters, indicating it is a full policy document rather than a brief announcement or certification.
2024-05-17 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.